La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Sino Biopharmaceutical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Sino Biopharmaceutical..

Sino Biopharmaceutical (OTC:SBHMY) Azioni, Catena delle Opzioni

Sino Biopharmaceutical

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

SINO BIOPHARM UNSP/ADR by Sino Biopharmaceutical Ltd.

Sino Biopharmaceutical Ltd

Trading Ideas

BREA

Brera Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 164.1%

Cryptocurrency markets are trading higher on Christmas eve, prompting traders to predict a bullish end to the year.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$98,100.74</td>
<td>+5%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,478.79</td>
<td>+4%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td> $196.49</td>
<td>+6%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.31</td>
<td>+6.1%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3338</td>
<td>+6.9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.0000231</td>
<td>+6.8%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 158.7%. Transactions greater than $100,000 are up from 7,495 to 10,784 in a single day. Exchanges netflows are down by 233.05%.</li>
<li>Coinglass data reports 88,733 traders were liquidated in the past 24 hours for $250.33 million.  </li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667518/deribit-eyes-growth-in-asset-backed-crypto-with-pax-gold-debut">Deribit Eyes Growth In Asset-Backed Crypto With Pax Gold Debut</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42667932/did-vladimir-putin-just-ban-bitcoin-mining-in-russia-the-devil-is-in-the-details">Did Vladimir Putin Just Ban Bitcoin Mining In Russia? The Devil Is In The Details</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42665539/north-korean-hackers-suspected-presence-triggers-over-500-million-in-outflows-from-crypto-exchange">North Korean Hackers&#8217; Suspected Presence Triggers Over $500 Million In Outflows From Crypto Exchange</a></li>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42666635/blackrocks-bitcoin-etf-could-outshine-sp-500-tracking-spy-to-become-top-investment-vehicle-but-it-will-take-a-long-time-says-prominent-analyst">Blackrock&#8217;s Bitcoin ETF Could Outshine S&amp;P 500-Tracking SPY To Become Top Investment Vehicle But It Will Take A &#8216;Long&#8217; Time, Says Prominent Analyst</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Pudgy Penguins (CRYPTO: PENGU)</td>
<td>&nbsp;$0.03587</td>
<td>+35.7%</td>
</tr>
<tr>
<td>Bitget Token (CRYPTO: )</td>
<td>&nbsp;$4.90</td>
<td>+21.9%</td>
</tr>
<tr>
<td>Virtuals Protocol (CRYPTO: VIRTUAL)</td>
<td>&nbsp;$3.13&nbsp;</td>
<td>+20.6%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Bitcoin prices are trading higher, and crypto trader Jelle has shared a straightforward strategy for navigating the market.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bull market Christmasses tend to be wild. Bull market Januaries tend to be bullish. Keep it simple. <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://t.co/Msb55w8EqN">pic.twitter.com/Msb55w8EqN</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1871111818732798092?ref_src=twsrc%5Etfw">December 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Rekt Capital <a href="https://x.com/rektcapital/status/1871577852291727666">observed</a> that Bitcoin attempted a relief rally yesterday but was rejected near recent lows. 
Today, it&#8217;s rebounding and testing former support levels, which now act as resistance. 
If resistance holds, further downside is likely. However, reclaiming these levels could signal a bullish reversal.
Trader Satoshi Flipper <a href="https://x.com/SatoshiFlipper/status/1871560106111914201">reflected</a> on Bitcoin&#8217;s recent 15% correction and altcoins dropping 25-50%. 
He questions whether this marks the local bottom or if future corrections will follow a similar pattern.
While its possible, certainty remains elusive. 
The trader wonders if history is repeating or rhyming, acknowledging it&#8217;s too early to draw conclusions. Investors can afford to wait, but traders remain cautious.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42668043/if-you-gave-your-loved-ones-a-150-bitcoin-christmas-gift-in-2022-itd-be-worth-more-than-what-an-average-american-spends-on-the-holiday-in-2024">If You Gave Your Loved Ones A $150 Bitcoin Christmas Gift In 2022, It&#8217;d Be Worth More Than What An Average American Spends On The Holiday In 2024</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Surge Around 5% In Christmas Eve 'Santa Rally'

Brera Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 118.4%

Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) are trading lower Tuesday. The stock is continuing the downtrend that began on Dec. 19 when, after the close, the company announced earnings and said it plans to <a href="https://www.benzinga.com/24/12/42623222/whats-going-on-with-fedex-stock-friday">separate its Freight Unit.</a>
The chart of FedEx shows some classic examples of what traders refer to as &#8220;bad action.&#8221; This is why our team of technical analysts has made it our Stock of the Day.
Action is something that can't be quantified. For example, if a company beats earnings and the stock moves down, it would be considered &#8220;bad action.&#8221; If a company misses earnings and the stock goes up it could be considered &#8220;good action.&#8221;
On Dec. 20, FedEx stock opened about $20 higher than the previous day's close. Traders and investors thought the news and earnings were bullish.
But by the close, the sellers overpowered the buyers. The shares reversed and gave back all of their gains. This was &#8220;weak action&#8221; that showed the bears were in charge.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back</a>
As you can see on the chart, FedEx broke the support that was at the $275 level. This was another example of &#8220;bad action.&#8221;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24115534/fdx-1024x554.png" alt="" class="wp-image-706297" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24115534/fdx-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24115534/fdx-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24115534/fdx-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/24115534/fdx.png 1488w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There tends to be support at prices that have been resistance. This happens because some people who sold at the resistance regretted doing so when the price eventually moved higher. They decide they will buy their shares back at the same price they were sold for if they can.
So, when the stock fell back to $275, they placed buy orders. This concentration of buy orders caused support to form.
But the support was only intact for 3 days. There were more sell orders than buy orders, which made the support break and resulted in another move lower.
The fact that there has been no rebound or bounce back is a third sign of &#8220;bad action.&#8221;
Typically, if a stock makes a large move lower, it is followed by some rebound or bounce, even though it may be small. If this doesn't happen, it shows that buyers are not entering the market, and the sellers are still in charge.
There is a good chance FedEx continues to head lower.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42671446/the-worlds-most-valuable-neurotech-company-builds-an-alarm-system-for-your-brain">The World&#8217;s Most Valuable Neurotech Company Builds an Alarm System for Your Brain</a></li>
</ul>
Photo: Shutterstock

Technicals

Stock Of The Day: FedEx Shows 'Bad Action' As Support Crumbles

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 200 points on Tuesday.
The Dow traded up 0.53% to 43,132.84 while the NASDAQ climbed 1.05% to 19,972.38. The S&amp;P 500 also rose, gaining, 0.78% to 6,020.96.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.8% on Tuesday.
In trading on Tuesday, health care shares rose by just 0.1%.
Top Headline
The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) shares shot up 13% to $7.00 after Waterous Energy Fund acquired 9,311,424 common shares and 2,654,179 common share purchase warrants of the company.</li>
<li>Shares of Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>)got a boost, surging 103% to $7.87 after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares were also up, gaining 73% to $5.91 after the company announced it launched &#8220;Ava&#8221; an agentic AI model for private jet booking.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Canoo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares dropped 8% to $1.4606.</li>
<li>Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) were down 8% to $24.80 after reporting fourth-quarter results.</li>
<li>Rigel Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) was down, falling 7% to $16.00.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $70.28 while gold traded up 0.1% at $2,630.20.
Silver traded up 0.1% to $30.205 on Monday, while copper rose 0.6% to $4.1085.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.17%, Germany's DAX fell 0.18% and France's CAC 40 rose 0.14%. Spain's IBEX 35 Index rose 0.33%, while London's FTSE 100 rose 0.42%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.32%, Hong Kong's Hang Seng Index gaining 1.08%, China's Shanghai Composite Index gaining 1.26% and India's BSE Sensex falling 0.09%.
Economics
<ul>
<li>U.S. Redbook index increased 5.9% year-over-year in the latest week, following a prior reading of 4.8% gain.</li>
<li>The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669068/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CREV

GOEV

JTAI

LMNR

RIGL

Dow Jumps Over 200 Points, Crude Oil Gains 1.5%

Meta Description: Amazon founder and tech titan Jeff Bezos saved nearly $1 billion in state taxes by relocating from Seattle to his billionaire bunker in Florida.
For most people, deciding where to live comes down to factors like affordability and access to employment. Then again, billionaires like<a href="https://www.benzinga.com/insights/analyst-ratings/24/12/42300654/navigating-50-analyst-ratings-for-amazon-com"> Amazon</a> founder Jeff Bezos aren't most people. Although Bezos has the money to live wherever he wants, many people suspect finances played a role in his decision to relocate to the infamous "billionaire bunker" in 2024. Keep reading to learn why that move may have saved<a href="https://www.benzinga.com/news/24/11/42254596/jeff-bezos-acts-like-he-owns-the-elite-neighborhood-he-lives-in-but-residents-say-hes-not-much-of-a-neighbor"> Jeff Bezos</a> almost $1 billion in taxes.
Like many billionaires, Jeff Bezos' life has become the subject of intense public speculation. Almost every move Bezos makes becomes news and his announcement in late 2023 that he would relocate to Florida is no exception. Bezos announced the move on his Instagram page, listing several motivating factors, including being closer to his parents and his fledgling aerospace company, Blue Origin.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/go/arrived-private-credit-yf">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
Bezos moved from Seattle, where he had lived for many years, to Indian Creek Village in early 2024. Indian Creek Village is an exclusive community outside of Miami known as the "billionaire bunker." Business Insider describes this as more than just a swanky gated community. It is its own city, with only 89 residents and a police department whose sole job is keeping nonresidents out.
Indian Creek Village is a private island and the only way in is to cross a bridge patrolled by its Police Department. The same department has a fleet of boats and aggressively patrols the surrounding waters. Even Before Bezos moved in, Indian Creek Village was home to an ultraexclusive crowd that included Tom Brady, Ivanka Trump and Carl Icahn. It's even rumored that the Emir of Qatar has a place there.
See Also: Unlock the hidden potential of commercial real estate —<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=unlockboost-yahoo"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
This explains why most of the media attention revolved around the sheer size of Bezos' acquisitions. He didn't just buy one place on the island; he bought three. According to an article in the Robb Report, Bezos spent almost $250 million on them. Ownership of the three properties gives Bezos control over 7.5% of Indian Creek Village's 40 residences.
It's not hard to imagine why Indian Creek Village's combination of exclusivity and privacy would appeal to someone like Jeff Bezos. However, astute financial observers began to speculate on another reason for Bezos' abrupt move from Washington to Florida. Forbes magazine has reported that Bezos has sold nearly $13.6 billion in Amazon stock since moving to Indian Creek Village.
Washington&#8217;s capital gains tax law taxes capital gains over $250,000 at 7%. Florida, by contrast, doesn't tax income or capital gains. Forbes estimates Bezos would have owed about $954 million to the state of Washington if he had still been living in Seattle when he sold his Amazon stock. Looking at it that way, spending $250 million on property saved Jeff Bezos $700 million.
Read Next:
<ul>
<li>Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today.<a href="https://smartasset.com/retirement/find-a-financial-planner?utm_source=benzinga&amp;utm_campaign=ben&amp;utm_content=y2_5MilNestEgg"> SmartAsset&#8217;s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost</a> to decide which one is right for you.</li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=jeffbezos100"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>

Real Estate

How Jeff Bezos Knocked $1 Billion Off His Tax Bill By Moving To His Infamous "Billionaire Bunker"

In the current session, TotalEnergies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) is trading at $54.07, after a 0.35% drop. Over the past month, the stock fell by 6.03%, and in the past year, by 20.89%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1735059607_0.png" alt="Past Year Chart" />

<h3>Evaluating TotalEnergies P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 13.72 in the Oil, Gas &amp; Consumable Fuels industry, TotalEnergies Inc. has a lower P/E ratio of 7.65. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1735059607_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

P/E Ratio Insights for TotalEnergies

IRBT

Watching iRobot; Shares See A Pop To The Upside As Traders Circulate Popular Stock Trader X Account Suggesting They Have Bought Shares

Achilles Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) shares are trading higher on Tuesday after the company announced a $12 million deal with AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42669546/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca" rel="noreferrer noopener">and plans to cut jobs.</a>
The agreement involves the transfer of the commercial license for data and tumor samples from Achilles&#8217; TRACERx Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca.
The million deal signals the conclusion of Achilles&#8217; strategic review, which was announced in September 2024.
In the wake of the deal&#8217;s completion, Achilles also rvealed plans to reduce its employee headcount and trim its Board of Directors, while staying compliant with Nasdaq and SEC requirements.
&#8220;Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors, while remaining compliant with Nasdaq and SEC requirements,&#8221; the company noted.
Also Read: <a href="https://www.benzinga.com/news/large-cap/24/12/42668623/american-airlines-resolves-nationwide-flight-grounding-on-christmas-eve-shares-rebound-after-brief-selloff">American Airlines Lifts Christmas Eve Grounding, Shares Bounce Back</a>
TRACERx, a study led by Professor Charles Swanton at University College London (UCL), has collected extensive genetic data from over 3,200 tumor samples from more than 800 lung cancer patients.
This multi-region, multi-time-point sequencing offers deep insights into cancer evolution and treatment responses.
As part of the deal, AstraZeneca will also take over Achilles&#8217; Material Acquisition Platform (MAP), which houses tumor samples and data collected from nearly 300 cancer patients across various solid tumor indications such as lung, melanoma and breast cancer.
&#8220;We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets,&#8221; said Dr. Iraj Ali, CEO of Achilles Therapeutics.
The company believes these assets have significant potential to aid in developing improved cancer therapies.
Price Action: ACHL shares are trading higher by 7.01% to $1.050 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42660092/microstrategy-sinks-after-nasdaq-100-inclusion-bitcoin-bet-under-fire" target="_blank" rel="noreferrer noopener">MicroStrategy Sinks After Nasdaq 100 Inclusion: Bitcoin Bet Under Fire?</a></li>
</ul>
Photo by Johaehn from Pixabay

Movers

General

ACHL

Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are hitting new highs on Tuesday. Here&#8217;s a look at <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">what&#8217;s going on</a>. 
What To Know: Palantir shares are up more than 380% since the start of the year, driven largely by the company&#8217;s positioning in the AI space. 
The rally in Palantir shares accelerated at the beginning of November after the company reported&nbsp;<a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele" target="_blank" rel="noreferrer noopener">strong quarterly results</a>&nbsp;driven by&nbsp;&#8220;unrelenting&#8221; AI demand.&nbsp;
Revenue jumped 30% year-over-year on continued strength in the U.S. and customer count grew 39% after the company closed 104 deals worth over $1 million during the quarter.
&#8220;The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,"&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders last month.
Check This Out: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42671903/investors-aggressively-bought-stocks-etfs-despite-fed-volatile-week-bank-of-america-reveals-largest-inflows-since-2017">Investors Aggressively Bought Stocks, ETFs In Volatile Fed Week: Bank Of America Reveals Largest Inflows Since 2017</a>
Over the weekend, the Financial Times <a href="https://www.ft.com/content/6cfdfe2b-6872-4963-bde8-dc6c43be5093">reported</a> that Palantir and defense technology company Anduril are communicating with several competitors about the potential of forming a consortium to make a joint bid on U.S. government contracts.
The report indicates that SpaceX and OpenAI are among the companies in talks to join. The group is planning to announce itself publicly as soon as January, people with knowledge of the matter said. 
"We are working together to provide a new generation of defense contractors," one person involved in organizing the group reportedly said. 
The Financial Times further reported that tie-ups between some tech groups expected to be involved with the consortium have already started. Palantir&#8217;s AI platform was integrated with Anduril&#8217;s autonomous software earlier this month and Anduril has linked its counter-drone systems with OpenAI models.
Palantir announced last week that it extended its long-standing partnership with the U.S. Army&nbsp;through 2028. The four-year agreement extension is valued at more than $400 million and has a total available ceiling of approximately $619 million. 
By leveraging Palantir&#8217;s software, the U.S. Army is able to create AI-enabled data solutions to analyze information from multiple data sources, enabling operational efficiencies and optimizing business processes.
PLTR Price Action: <a href="http://benzinga.com/quote/pltr">Palantir shares </a>were trading at all-time highs at last check. The stock was up 1.31% at $81.79 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

PLTR

Palantir Stock Is Trading At All-Time Highs: What's Going On?

The Biden administration withdrew two major student loan forgiveness plans Friday, just weeks before President-elect Donald Trump returns to the White House. Here's a look at what it means for borrowers and student <a href="https://www.benzinga.com/markets/equities/24/12/42635567/biden-student-loan-forgiveness-tops-180-billion-with-latest-relief">loan service providers.</a> 
The Details: The Education Department posted notices in the Federal Register that it was withdrawing two proposals that could have reduced student loan debt for millions of borrowers, including those with financial hardship and those who have been in repayment for years, CNBC reported. 
Read Next: <a href="https://www.benzinga.com/news/24/12/42669113/waymos-autonomous-vehicles-are-safer-than-human-drivers-report">Waymo&#8217;s Autonomous Vehicles Are Safer Than Human Drivers: Report</a>
The department wrote that it was withdrawing the proposed rules due to "operational challenges in implementing the proposals." It also said it would focus its resources on "helping at-risk borrowers return to repayment successfully" as the administration prepares to leave office in the next month.&nbsp;
"The Biden administration knew that the proposals for broad student loan forgiveness would have been thwarted by the Trump administration," higher education expert Mark Kantrowitz<a href="https://www.cnbc.com/2024/12/23/student-loan-forgiveness-plans-withdrawn-by-biden-administration.html"> told</a> CNBC.&nbsp;
What Else: Also on Friday, the Department of Education announced another $4.28 billion in<a href="https://www.ed.gov/about/news/press-release/biden-harris-administration-approves-additional-428-billion-student-debt-relief-nearly-55000-public-service-workers-0"> loan forgiveness</a> for nearly<a href="https://www.benzinga.com/topic/student-debt"> 55,000 public service workers</a> which brought the total amount of student loan forgiveness under the Biden administration to $180 billion.
Education Secretary Miguel Cardona emphasized the administration's commitment to student loan relief for public service workers in a statement Friday. 
"Four years ago, the Biden-Harris Administration made a pledge to America&#8217;s teachers, service members, nurses, first responders, and other public servants that we would fix the broken Public Service Loan Forgiveness Program, and I&#8217;m proud to say that we delivered," Cardona said.
Loan Servicers: The administration's withdrawal of the additional loan forgiveness proposals is potentially a positive development for student loan providers including SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), Navient Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) and SLM Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>)&nbsp;
Student loan providers would have lost revenue if Biden's student loan forgiveness plans had gone through. 
Additionally, the rollout of forgiveness programs often requires servicers to update systems, retrain staff and manage complex transitions, all of which would increase expenses.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">&#8216;Santa Came Early&#8217; But Fed Brings &#8216;Coal Next Year&#8217;: Experts Weigh In On Interest Rate Cut, 2025 Projections</a></li>
</ul>
Image: Shutterstock.

Government

Education

Politics

Legal

NAVI

SOFI

Biden Dumps Student Loan Forgiveness Plans: What It Means For Borrowers, Loan Providers Like SoFi

Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares are trading higher after it entered into a securities purchase agreement <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42668635/carmell-announces-pipe-investment-from-existing-and-new-investors-to-support-commercial-build-out" rel="noreferrer noopener">with new and existing investors</a>.
The agreement involves the issuance and sale of 8,065,210 shares of common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement.
The transaction is expected to generate gross proceeds of $1.85 million before offering expenses and fees.
If the warrants are exercised, Carmell could receive an additional $1.85 million.
The Private Placement was priced slightly above CTCX&#8217;s closing price on Dec. 23, 2024.
Following the closing of the Private Placement, Carmell Corporation will have approximately 29 million shares of common stock outstanding.
The warrants can be exercised starting the trading day after the Stockholder Approval Date and continue until the fifth anniversary of the warrant issue date.
The warrants allow for the purchase of up to 8.1 million shares of Carmell&#8217;s common stock at an exercise price of $0.23 per share.
The closing of the Private Placement is subject to customary conditions.
Price Action: CTCX shares are up 20% at $0.27 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Warren Buffett Heads Into 2025 With $325 Billion Cash Pile, His Largest in Over Three Decades: Expert Says It &#8216;Will Provide An Opportunity For The Successors To Make Their Own Mark&#8217;</a></li>
</ul>
Photo: Shutterstock

Financing

Small Cap

CTCX

Why Biotechnology Company Carmell Shares Are Seeing Blue Skies Tuesday?

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) has outperformed the market over the past 10 years by 1.41% on an annualized basis producing an average annual return of 12.59%. Currently, Agilent Technologies has a market capitalization of $38.44 billion. 
Buying $100 In A: If an investor had bought $100 of A stock 10 years ago, it would be worth $327.79 today based on a price of $134.60 for A at the time of writing.
<h3>Agilent Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735058734_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years

WIIM

EVTL

Vertical Aerospace shares are trading higher. The company announced it has finalized an investment agreement for up to $50M in new funding.

Brera Holdings Shares Resume Trade

Brera Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 52.8%

Graphjet Technology Shares Halted On Circuit Breaker To The Downside, Stock Now Up 164.3%

Over the past year, OpenAI has dropped not-so-subtle hints about its revived interest in robotics: investing in startups developing hardware and software for robots such as Figure and Physical Intelligence and rebooting its internal robotics software team, which it had disbanded four years ago. Now, OpenAI could be taking that interest to the next level. The company has recently considered developing a humanoid robot, according to two people with direct knowledge of the discussions. &nbsp;As a refresher, humanoid robots typically have two arms and two legs, distinguishing them from typical robots in a warehouse or factory that might have a single arm repeatedly performing the same task on an assembly line. Developers of humanoid robots think it will be easier for them to handle tasks in the physical world—which is tailored to humans—than it would be to change our physical environments to suit new robots. Don't get too excited yet, though: Any potential humanoid robot seems to be a lower priority for OpenAI than a number of its other technologies and products, such as its highly praised reasoning models and an agent that could help automate all manner of software engineering and analysis tasks, one of these people said.
<a href="https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot" title="https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot">https://www.theinformation.com/articles/openai-has-discussed-making-a-humanoid-robot</a> &nbsp;

MSFT

TSLA

'OpenAI Has Discussed Making a Humanoid Robot' - The Information

Graphjet Technology Shares Resume Trade

Brera Holdings Shares Halted On Circuit Breaker To the Upside, Stock Now Up 29.9%

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts' earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let's look at its financial metrics to gauge its prospects… On May 6, 2024, Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), a pharmaceutical company pioneering in the field of Cystic Fibrosis (CF), reported solid first-quarter results as the company saw progress in its R&amp;D pipeline. Its net product revenues increased 13.3% year-over-year to $2.69 billion, while its non-GAAP <a href="https://www.investopedia.com/terms/o/operatingearnings.asp">operating income</a> surged 48.1% from the prior-year quarter to $1.34 billion.
Additionally, its non-GAAP net income came in at $1.24 billion or $4.76 per common share, representing more than a 56% year-over-year increase. However, as of March 31, 2024, VRTX's cash and cash equivalents and marketable securities amounted to $10.17 billion, down from $11.22 billion as of December 31, 2023.
Moreover, the company comprehensively surpassed Wall Street's EPS and revenue estimates. For the first quarter, VRTX's earnings per share was 17.2% above the consensus estimate, and its revenue was 4.3% higher than the analysts' estimates. It is no surprise that VRTX's strong earnings have topped the EPS estimates in each of the past consecutive four quarters.
Shares of VRTX have gained 18.8% over the past nine months and 17.9% over the past year to close the last trading session at $410.24.
Here are the fundamental aspects of VRTX that could influence its price performance in the near term:
Positive Developments
Last month, the company entered into a definitive agreement to acquire Alpine Immune Sciences, Inc. (<a href="https://stocknews.com/stock/ALPN/">ALPN</a>) for approximately $4.9 billion in cash. This deal includes obtaining povetacicept, a Phase 3-ready asset known for its potential in treating IgA nephropathy and its status as a potential pipeline-in-a-product.
VRTX's CEO, Reshma Kewalramani, views the acquisition as strategically advantageous, as it aligns with The company's mission to address unmet needs in specialty markets. Further, this move aims to integrate ALPN's protein engineering and immunotherapy capabilities into the VRTX's portfolio.
On top of this, VRTX reached a clinical milestone for VX-670 in DM1 in the first quarter of 2024, triggering a $75 million milestone payable to Entrada.
Favorable Analyst Estimates
The consensus revenue estimate of $2.66 billion for the fiscal second quarter (ending June 2024) represents a 6.7% increase year-over-year. The consensus EPS estimate of $4.17 for the current quarter indicates a 7.2% improvement year-over-year. The company has an excellent surprise history, surpassing the consensus revenue estimates in three of the trailing four quarters.
VRTX's revenue and EPS for the current year (ending December 2024) are expected to grow 9% and 11.6% year-over-year to $10.75 billion and $17.02, respectively. Looking ahead, analysts forecast an 8.8% and 6.7% year-over-year growth in VRTX's revenue and EPS for fiscal year 2025, projecting figures of $11.70 billion and $18.16, respectively.
Discounted Valuation
In terms of forward non-GAAP PEG, VRTX is currently trading at 0.75x, 60.5% lower than the industry average of 1.89x. Its forward P/E multiple of 26.19 is 4.5% lower than the industry average of 27.53x.
In addition, the stock's trailing-12-month EV/EBIT of 20.50x is 9.6% lower than the 23.18x industry average.
Robust Profitability
VRTX's trailing-12-month EBITDA margin of 44.87% is 728.8% higher than the 5.41% industry average. The stock's trailing-12-month levered FCF margin of 35.57% is significantly higher than the 0.53% industry average.
Further, its trailing-12-month net income margin, ROCE, and ROTA of 39.46%, 24.38%, and 16.81% compares to the negative industry averages of 5.52%, 40.87%, and 29.54%, respectively.
POWR Ratings Exhibit Solid Prospects
VRTX's solid outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories.
VRTX boasts a B grade for Value, mirroring its discounted valuation. Additionally, it also earns a B for Quality, reflecting its superior profitability metrics compared to industry standards.
The stock is ranked #8 out of 359 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/VRTX/">Click here</a> to access VRTX's Growth, Momentum, Stability, and Sentiment ratings.
Bottom Line
VRTX kicked off the year on a strong note, with sharp increases in profits and revenue in the first quarter, primarily fueled by the robust uptake of Trikafta among younger patients. Moreover, the anticipation of regulatory approvals for VRTX's therapies across various global regions signals a promising outlook for the company's expansion and market reach.
Additionally, the company's reaffirmed revenue guidance for fiscal year 2024 (total product revenues are expected to range from $10.55 billion to $10.75 billion) reflects a confident outlook for sustained growth in the cystic fibrosis sector, alongside the potential introduction of Casgevy in new indications and markets.
Plus, the activation of treatment centers for Casgevy and the collection of cells from patients for its commercial launch in sickle cell disease and transfusion-dependent Beta-thalassemia are some promising developments.
Given these factors, coupled with robust profitability, optimistic analyst estimates, and discounted valuation underscore the company's strong financial position and the potential for future earnings growth.
Hence, we believe that investing in this stock could help you garner substantial returns.
How does Vertex Pharmaceuticals Incorporated (VRTX) Stack Up Against its Peers?
Other stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> sector that may be worth considering are Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>), Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), and Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>) - they have an overall rating of A (Strong Buy). <a href="https://stocknews.com/category/biotech/">Click here</a> to explore more Biotech stocks.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
VRTX shares were trading at $423.48 per share on Wednesday afternoon, up $13.24 (+3.23%). Year-to-date, VRTX has gained 4.08%, versus a 9.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vrtx-sbhmy-gild-otsky-alpn-vertex-pharmaceuticals-vrtx-earnings-review-is-it-time-to-buy/>Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

Sino Biopharmaceutical Limited goes ex dividend tomorrow

Given Organogenesis's (ORGO) upbeat first-quarter results and promising development of its ReNu program for knee osteoarthritis, the company seems to be on the brink of significant growth. Let's delve into its fundamentals to determine whether it's a hidden gem in the biotech sector. Read more to find out… Leading wound care specialist Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>) surpassed Wall Street's expectations in the first quarter of fiscal 2024. The company reported revenue of $109.98 million, well above the analysts' estimate of $100.23 million. This figure also outpaced their guidance, which projected revenue between $98 million and $104 million, driven by a surge in momentum from February into March.
Building on the momentum, Organogenesis forecasts positive growth for the year ending December 31, 2024. The company expects net revenue to range between $445 million and $470 million, marking a year-over-year increase of 3% to 9% compared to the $433.1 million reported for 2023. However, the profitability outlook is mixed, with expected adjusted <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> (loss) ranging from ($8.1) million to $7.1 million and adjusted EBITDA between $15.8 million and $35.0 million.
While revenue growth is strong, Organogenesis has been experiencing an unsettling string of earnings contractions, which could pose a challenge in the near term. ORGO's net loss per share was $0.02, compared to the consensus estimate of 0.03.
Shares of ORGO have gained 1.5% over the past month to close the last trading session at $2.70. However, the stock has plunged 21.9% over the past year and 33.7% year-to-date.
Let's look at factors that could influence ORGO's performance in the upcoming months.
Promising Progress in ReNu Phase III Clinical Trials
Organogenesis has made notable progress with its ReNu program, which aims to manage knee osteoarthritis (OA) symptoms. Recently, the company shared<a href="https://investors.organogenesis.com/news-releases/news-release-details/organogenesis-achieves-primary-endpoint-phase-3-clinical-trial"> positive top-line results</a> from its first Phase III clinical trial, achieving the primary endpoint with a p-value of 0.0177. The trial demonstrated a significant reduction in knee OA pain over six months compared to a saline control group.
By 2027, an estimated 34.4 million Americans will be affected by knee OA. ReNu could offer a non-surgical pain management option, particularly for the most severe cases, representing around 5 million people. If approved, ReNu would be the only FDA-approved biologic intra-articular injection for this purpose, marking a significant advancement in the treatment of knee OA.
Mixed Financial Performance
For the first quarter that ended March 31, 2024, ORGO's net revenues increased 2.2% year-over-year to $109.98 million. Revenue from Advanced Wound Care rose 3% from the prior year to $103.9 million, while the net revenue for Surgical and Sports Medicine products was $6.1 million, down 9% year-over-year. Its gross profit grew marginally from the year-ago value to $81.28 million.
ORGO's loss from operations narrowed 3.7% from the previous year's quarter to $3.85 million. The company's net loss came in at $2.10 million compared to $2.97 million last year, while its net loss per share remained flat year-over-year at $0.02. However, ORGO recorded an adjusted EBITDA of $2.55 million in the same quarter.
As of March 31, 2024, Organogenesis' cash and cash equivalents stood at $88.63 million, compared to $103.84 million as of December 31, 2023.
Mixed Analyst Estimates
Analysts expect ORGO's EPS to increase 5.7% year-over-year to $114.73 million for the third quarter ending September 2024. For the fiscal year ending December 2024, its revenue is expected to reach $453.76 million, registering a year-over-year growth of 4.8%.
However, the company is estimated to post a loss per share of $0.01 in the current quarter and remain negative for the fiscal year 2024. Nonetheless, ORGO has an impressive earnings surprise history, surpassing the consensus EPS estimates in three of the trailing four quarters.
Discounted Valuation
In terms of forward EV/Sales, ORGO is trading at 0.88x, which is 74.2% lower than the industry average of 3.42x. Similarly, the stock's forward Price/Sales multiple of 0.82 is 76.9% lower than the industry average of 3.54x. Additionally, the stock's 2.64x forward Price/Book is 1.2% below the industry average of 2.67x.
POWR Ratings Reflect Uncertainty
ORGO's mixed fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ORGO has an A grade in Value, which aligns with its lower-than-industry valuation. However, with a five-year beta of 1.66, the stock has earned a grade C for Stability.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, ORGO is ranked #47 out of 342 stocks.
Beyond what I have stated above, we have also given ORGO grades for Growth, Momentum, Sentiment, and Quality. Get all ORGO ratings <a href="https://stocknews.com/stock/ORGO/">here</a>.
Bottom Line
Organogenesis is an anomaly among small biotechs, achieving modest revenues despite inconsistent earnings and a promising catalyst in ReNu. However, this inconsistency in earnings has proven to be a significant stumbling block. While optimism about its long-term potential is contingent upon securing FDA approval for ReNu, recent mixed financial performance and an uncertain near-term outlook raise concerns.
Given these uncertainties and the volatility typically associated with biotech investments, waiting for a better entry point in this stock seems wise now.
How Does Organogenesis Holdings Inc. (ORGO) Stack Up Against Its Peers?
Given its near-term uncertain prospects, the odds of ORGO outperforming in the weeks and months ahead are compromised. However, there are many industry peers with much more impressive POWR Ratings. So, consider these three A (Strong Buy) stocks from the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Nippon Shinyaku Co., Ltd. (<a href="https://stocknews.com/stock/NPPNY/">NPPNY</a>), and Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>).
To explore more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ORGO shares were trading at $2.74 per share on Monday afternoon, down $0.06 (-2.14%). Year-to-date, ORGO has declined -33.01%, versus a 15.51% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/orgo-gild-nppny-sbhmy-is-organogenesis-a-hidden-gem-in-the-biotech-sector/>Is Organogenesis a Hidden Gem in the Biotech Sector?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Organogenesis a Hidden Gem in the Biotech Sector?

Veracyte (VCYT) exceeded Wall Street's expectations in its first-quarter earnings report and is well-positioned to capitalize on the expanding genomic diagnostics market. However, with its stretched valuation and increased volatility, is VCYT a smart investment? Read on to find out… Genetic testing, a critical medical procedure, identifies alterations in genes, chromosomes, or proteins to confirm or rule out genetic conditions and assess an individual's risk of developing or passing on such disorders. This market is booming, with the global genetic testing market projected to grow from $8.84 billion in 2023 to an estimated <a href="https://www.biospace.com/article/releases/genetic-testing-market-size-to-set-usd-64-73-billion-by-2033/">$64.73 billion by 2033</a>, driven by technological advancements, increased awareness, and expanding applications. The U.S. genomics market alone is set to reach around $43.81 billion by 2032, growing at a <a href="https://www.precedenceresearch.com/genomics-market#:~:text=The%20U.S.%20genomics%20market%20size,the%20Middle%20East%2C%20and%20Africa.">CAGR of 19.4%</a>.
Thus, it could be opportune to invest in fundamentally sound biotech stocks. Let's determine whether investors should place their bets on Veracyte, Inc. (<a href="https://stocknews.com/stock/VCYT/">VCYT</a>) in genomic diagnostics.
VCYT is a leading diagnostics company that aims to revolutionize cancer care globally through innovative diagnostics. By leveraging a powerful platform of genomic data, bioinformatics, and AI, Veracyte provides clinicians with vital insights needed for accurate cancer diagnosis and treatment guidance.
The company's first-quarter earnings for 2024 painted a promising picture, with revenue of $96.84 million, exceeding Wall Street expectations of $93.36 million. Its test volume rose by 16% year-over-year to 33,424.
One of Veracyte's significant achievements is the Decipher Prostate Genomic Classifier, which received top-tier recognition in the updated NCCN prostate cancer guidelines. Additionally, VCYT's acquisition of C2i Genomics has broadened its capabilities into minimal residual disease (MRD) testing, marking a significant expansion in its product offerings.
Marc Stapley, Veracyte's CEO, said, "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to further penetrate these markets by expanding our clinical evidence, and, for Decipher, securing enhanced status in guidelines while also achieving a key commercial reimbursement milestone."
Looking ahead, VCYT has raised its full-year 2024 revenue guidance to $402 million to $410 million, representing a year-over-year growth of 11% to 14% and testing growth of 15% to 18%. This optimism is supported by their expectations of ending the year with cash, cash equivalents, and short-term investments ranging from $236 million to $240 million.
Despite these advancements, shares of VCYT have plunged 17.4% over the past six months and 21.9% year-to-date to close the last trading session at $21.47. However, the stock has shown a recent uptick, gaining 4.1% over the past three months.
Let's look at factors that could influence VCYT's performance in the upcoming months.
Mixed Financial Performance
For the first quarter that ended March 31, 2024, VCYT's total revenue increased 17.5% year-over-year to $96.84 million. The company's testing revenue increased by 25% to $90.30 million, up from $72.40 million in the same period last year, primarily driven by the strong performance of the Decipher Prostate and Afirma tests. 
Its non-GAAP income from operations came in at $3.83 million, compared to the prior-year quarter's loss of $1.75 million. The quarter's <a href="https://www.investopedia.com/terms/n/netloss.asp">net loss</a> narrowed 76.9% and 81.8% year-over-year to $1.86 million and $0.02 per share, respectively.
However, VCVY's net cash used in operating activities for the quarter increased to $8.97 million from the year-ago value of $2.17 million. Additionally, as of March 31, 2024, VCYT's cash and cash equivalents stood at $209.19 million, compared to $216.45 million as of December 31, 2023.
Mixed Analyst Expectations
Analysts expect VCYT's revenue for the second quarter (ended June 2024) to grow 10.7% year-over-year to $99.99 million. However, the company is expected to post a loss per share of $0.01 in the same quarter.
Similarly, for the ongoing quarter (ending September 2024), VCYT's revenue is expected to increase 12% year-over-year to $100.95 million. On the contrary, its loss per share for the quarter is estimated to be $0.03.
Nonetheless, for the fiscal year ending December 2024, Street expects VCYT's revenue to grow 12.3% from the prior year to $405.60 million, while its EPS is expected to be $0.01.
Stretched Valuation
In terms of forward non-GAAP P/E, VCYT is trading at 1717.60x, significantly higher than the industry average of 18.81x. The stock's forward EV/Sales and Price/Sales multiples of 3.57 and 4.05 are 8.2% and 14.3% above the respective industry averages of 3.30 and 3.54.
Likewise, its forward EV/EBITDA of 50.88x is 297.6% higher than the industry average of 12.80x. Moreover, the stock's forward Price/Cash Flow ratio of 93.35x compares to the industry average of 14.94x.
Mixed Profitability
VCYT's trailing-12-month gross profit margin of 67.69% is 17.7% higher than the 57.48% industry average. Also, the stock's trailing-12-month levered FCF margin of 9.75% is considerably higher than the industry average of 1.26%.
However, its trailing-12-month asset turnover ratio of 0.32x is 21.6% lower than the industry average of 0.41x. Likewise, the stock's trailing-12-month EBITDA margin of 5.25% is 9.6% lower than the industry average of 5.81%.
POWR Ratings Reflect Uncertainty
VCYT's mixed fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. VCYT has a C grade for Sentiment, which is consistent with mixed analyst estimates.
The stock also has a C grade for Quality, justified by its mixed profitability. Moreover, with a five-year beta of 1.64, the stock has earned a grade C for Stability.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, VCYT is ranked #60 out of 336 stocks.
Beyond what I have stated above, we have also given VCYT grades for Value, Momentum, and Quality. Get all VCYT ratings <a href="https://stocknews.com/stock/VCYT/">here</a>.
Bottom Line
VCYT exceeded analysts' revenue and earnings estimates in the first quarter of 2024, buoyed by strategic market expansion and robust clinical advancements. Despite significant improvement from the previous year's losses, the company continues to face a negative bottom line.
As Veracyte navigates the dynamic landscape of genomic diagnostics, it's crucial to assess whether its innovative approach and strong market position make it a smart bet for investors looking to capitalize on the growth of genetic testing.
Given VCT's elevated valuation and uncertain near-term outlook, waiting for a better entry point in this stock seems wise now.
How Does Corsair Gaming, Inc. (VCYT) Stack Up Against Its Peers?
While VCYT has an overall grade of C, equating to a Neutral rating, you may check out these A (Strong Buy) rated stocks within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Nippon Shinyaku Co., Ltd. (<a href="https://stocknews.com/stock/NPPNY/">NPPNY</a>), and Sino Biopharmaceutical Limited (<a href="https://stocknews.com/stock/SBHMY/">SBHMY</a>).
To explore more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>
 

<hr />
VCYT shares were trading at $21.47 per share on Friday afternoon, down $0.00 (0.00%). Year-to-date, VCYT has declined -21.96%, versus a 17.16% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/vcyt-gild-nppny-sbhmy-is-veracyte-a-smart-bet-in-genomic-diagnostics/>Is Veracyte a Smart Bet in Genomic Diagnostics?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Sino Biopharmaceutical

Sino Biopharmaceutical (SBHMY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO